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Many bacteria have evolved ways to interact with glycosylation
functions of the immune system of their hosts. Streptococcus
pyogenes [GAS (group A Streptococcus)] secretes the enzyme
EndoS that cleaves glycans on human IgG and impairs the effector
functions of the antibody. The ndoS gene, encoding EndoS,
has, until now, been thought to be conserved throughout the
serotypes. However, in the present study, we identify EndoS2, an
endoglycosidase in serotype M49 GAS strains. We characterized
EndoS2 and the corresponding ndoS2 gene using sequencing,
bioinformatics, phylogenetic analysis, recombinant expression
and LC–MS analysis of glycosidic activity. This revealed that
EndoS2 is present exclusively, and highly conserved, in serotype
M49 of GAS and is only 37% identical with EndoS. EndoS2
showed endo-β-N-acetylglucosaminidase activity on all N-linked
glycans of IgG and on biantennary and sialylated glycans of AGP
(α1-acid glycoprotein). The enzyme was found to act only on
native IgG and AGP and to be specific for free biantennary glycans
with or without terminal sialylation. GAS M49 expression of
EndoS2 was monitored in relation to carbohydrates present in the
culture medium and was linked to the presence of sucrose. We
conclude that EndoS2 is a unique endoglycosidase in serotype
M49 and differs from EndoS of other GAS strains by targeting
both IgG and AGP. EndoS2 expands the repertoire of GAS
effectors that modify key glycosylated molecules of host defence.
Key words: α1-acid glycoprotein, endo-β-N-acetylglucosamini-
dase, host–pathogen interaction, IgG glycosylation, Streptococ-
cus pyogenes.
INTRODUCTION
Glycosylation is a common post-translational modification, and
almost all key molecules in the immune system are glycosylated
[1]. IgG is the most abundant antibody in serum with the capacity
to bind and neutralize antigens, facilitate antibody-dependent
cytotoxicity, opsonize antigens and initiate phagocytosis. IgG is
composed of two light and two heavy chains, of which the latter
are glycosylated with complex N-linked glycans at Asn297. The
presence and structure of this glycan is of major importance for
the interaction of the antibody with Fcγ Rs (Fcγ receptors) and
for the subsequent effector functions elicited by the antibody
[2–4]. The glycan is present in a pocket of the two heavy chains
of the IgG molecule, where it has been shown to be flexible and
dynamic allowing it to influence the glycan–protein interaction
with Fcγ R [5]. IgA, IgD, IgE and IgM each carry several occupied
N- and O-linked glycosylation sites, and the study of the glycan’s
impact on the effector functions of these immunoglobulins has
only begun [6].
Streptococcus pyogenes [GAS (group A Streptococcus)] is
a leading Gram-positive bacterial pathogen exhibiting a wide
array of immune evasion mechanisms, including interference
with host glycosylation [7]. Every year, this bacterium causes
over 500000 deaths due to severe infections and post-infectious
immunological disorders: invasive infections, rheumatic fever,
glomerulonephritis and hundreds of millions of cases of milder
and self-limiting infections, such as pharyngitis and impetigo [8].
GAS is subdivided into serotypes on the basis of the antigenic
M-protein on the bacterial surface and there are currently over
100 serotypes described [9].
An endoglycosidase from S. pyogenes, EndoS, was discovered
in serotype M1 of GAS and found to hydrolyse the N-linked
glycan on the heavy chain of native human IgG and in this
way modulate the binding of IgG to Fcγ R [10–12]. EndoS (EC
Abbreviations used: 2-AB, 2-aminobenzamide; ABS, Arthrobacter ureafaciens sialidase; AGP, α1-acid glycoprotein; AMF, almond meal α-fucosidase;
BEH, bridged ethane–silicon hybrid; BKF, bovine kidney α-fucosidase; BTG, bovine testes β-galactosidase; CM, C-medium; CcpA, catabolite control protein
A; FcγR, Fcγ receptor; FLD, fluorescence detection; GAS, group A Streptococcus; GH18, family 18 of glycoside hydrolases; HILIC, hydrophilic interaction
liquid chromatography; HRP, horseradish peroxidase; LCA, Lens culinaris agglutinin; 4MU-GlcNAc, 4-methylumbelliferyl N-acetyl-β-D-glucosaminide;
MWCO, molecular-mass cut-off; NAN1, neuraminidase/sialidase 1; PNGase F, peptide N-glycosidase F; r, recombinant; UHPLC, ultra-HPLC.
1 To whom correspondence should be addressed (email jonathan.sjogren@med.lu.se).
2 Patents for the use of EndoS2 have been applied for by Genovis AB. Jonathan Sjögren, Andrew Hollands, Victor Nizet, Maria Allhorn and Mattias
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3.2.1.96) belongs to GH18 (family 18 of glycoside hydrolases)
and has endo-β-N-acetylglucosaminidase activity (CAZy, 2012;
http://www.cazy.org). Enzymes in the family GH18 hydrolyses
β-1,4-linked GlcNAc and this group of enzymes contains both
chitinases (EC 3.2.1.14) hydrolysing the carbohydrate chitin and
endo-β-N-acetylglucosaminidases (EC 3.2.1.96) with described
endoglycosidase activity on the chitobiose core of N-linked
complex glycans (CAZy, 2012).
EndoS is expressed in late stationary phase during streptococcal
growth and the catalytically active glutamate residue (Glu235) and
several tryptophan residues are required for enzymatic activity
[13]. Different from other described bacterial endoglycosidases,
EndoS hydrolyses the N-linked glycan only on native and not
denatured IgG [14]. Complement activation by the classical
pathway was reduced when antibodies were treated with EndoS
[11]. In human blood, the recombinant enzyme has been shown
to deglycosylate IgG, and, in an opsonophagocytic killing assay,
recombinant EndoS was shown to increase bacterial survival
[11]. The contribution of EndoS to GAS virulence has been
studied in a mouse model of invasive infection, and, although
of minor importance in the wild-type M1 bacteria, it increased
virulence of other GAS strains when heterologously expressed
[15]. As a strategy to treat autoimmune diseases, EndoS has
shown promise as a biotherapeutic in a number of animal
models of autoimmunity [16–21]. For the biotechnology industry,
the enzyme has applications both as a tool in the analysis
of monoclonal antibodies (Genovis AB) and potentially for
chemoenzymatic glycoengineering [22,23].
In the genome of GAS strain NZ131 of serotype M49, we
have identified the gene ndoS2 encoding the enzyme EndoS2
[24]. ndoS2 holds 53% identity with ndoS and the proteins
EndoS2 and EndoS are 37% identical. The GAS strain NZ131
is a clinical isolate from a case of acute post-streptococcal
glomerulonephritis in New Zealand [24]. Serotype M49 belongs
to a serotype grouping of GAS associated with skin infections
and glomerulonephritis, group II (M2, M42, M49, M56, M57 and
M60), rather than throat infections and rheumatic fever (M1, M4,
M12 and M25) that define group I [24,25].
In the present study, we characterize EndoS2 using
bioinformatics, recombinant expression and LC–MS analysis to
study the glycosidic activity.
MATERIALS AND METHODS
Bacterial strains and growth
The genome of S. pyogenes GAS strain NZ131 of serotype
M49 has been sequenced and this strain was therefore selected
as the reference strain in the present study [24,25]. GAS
was propagated on blood agar, Escherichia coli strains Top10
(Invitrogen) and BL21 pLysS (Invitrogen) were propagated on
lysogeny broth agar and used for cloning and recombinant
expression. All strains used are summarized in Supplementary
Table S1 (http://www.biochemj.org/bj/455/bj4550107add.htm).
For selection in E. coli Top10 cells, carbenicillin was used
at 100 μg·ml− 1 and, for E. coli BL21 pLysS, 100 μg·ml− 1
carbenicillin and 34 μg·ml− 1 chloramphenicol were used.
Overnight cultures of E. coli were carried out in lysogeny
broth at 37 ◦C with aeration. Genomic DNA preparation of
GAS strain NZ131 was performed using Puregene DNA
Purification Kit (Qiagen). Transformation was carried out
using heat-shock at 42 ◦C for 30 s. Plasmid preparations
from E. coli were performed using Plasmid Miniprep Kit I
(Omega Bio-Tek). All primers used are listed in Supplementary
Table S2 (http://www.biochemj.org/bj/455/bj4550107add.htm).
Expression of EndoS2 was studied using growth of NZ131 in
50% CM (C-medium) [0.5 % Proteose Peptone, 1.5% (w/v)
yeast extract, 10 mM K2PO4, 0.4 mM MgSO4 and 17 mM NaCl
(pH 7.5)].
Sequencing of ndoS2
Five GAS serotype M49 strains were selected for sequencing
of the ndoS2 gene; 3487-05, AP49, ACN49, AW1 and AW2.
Sequencing was carried out using primers ndoS2-out-R, seq38-R,
seq42-R, seq54-R, seq15-F, seq17-F, seq24-F and seq28-F and
the Lightrun sequencing service of GATC Biotech (Konstanz,
Germany). All primers used for sequencing are summarized in
Supplementary Table S2. The sequences have been deposited
in GenBank® with accession numbers as follows: KC155346
(strain 3487-05), KC155348 (strain AP49), KC155347 (strain
ACN49), KC155349 (strain AW1), KC155350 (strain AW2)
(Supplementary Table S2).
Recombinant expression of EndoS2
Recombinant expression of EndoS2 in E. coli was
established by PCR amplification of the ndoS2 gene
from GAS NZ131 with the primers ndoS2-F-BamHI,
5′-CTGTAAGGATCCAGGAGAAGACTG-3′, and ndoS2-R-
XhoI, 5′-GAAACCTCGAGTCTTTGTAATCGTAGGACTT-3′.
The ndoS2 fragment was digested with restriction enzymes
BamHI and XhoI (restriction sequences are underlined) and
ligated into the expression vector pGEX-5X-3 (GE Healthcare)
using DNA ligase T4 (Thermo Fisher Scientific) creating the
plasmid pGEX-ndoS2. The expression vector was transformed
into E. coli Top10 chemically competent cells and screened
with PCR using primers ndoS2-F-BamHI and ndoS2-R-XhoI.
Positive clones were isolated and the pGEX-ndoS2 plasmid
was purified and transformed into the E. coli expression strain
BL21 pLysS. One recombinant clone was grown overnight at
37 ◦C with antibiotics, diluted 1:20 in lysogeny broth medium
with antibiotics and grown for 3 h to mid-exponential phase.
The expression of the protein GST–EndoS2 was induced with
0.1 mM IPTG for 3 h. The cells were harvested and lysed
with BugBuster Protein Extraction Reagent (Novagen/Merck).
Recombinant GST–EndoS2 was purified on a column
with glutathione–Sepharose 4B (GE Healthcare) and eluted with
reduced glutathione. The GST tag was cleaved off using Factor
Xa (New England BioLabs). Site-directed mutagenesis was
performed on pGEX-ndoS2 using a QuikChange® II Site-
Directed Mutagenesis Kit (Agilent) with primers ndoS2(E-L)-
F and ndoS2(E-L)-R, to exchange the glutamate residue (E) in
the active site to leucine (L). Recombinant EndoS2(E186L) was
cloned and expressed in a similar way to EndoS2.
Phylogenetic analysis
We searched non-redundant protein databases at NCBI with
the BLASTP algorithm, submitting the EndoS2 sequence of
GAS strain ACN49 (M49). We retrieved similar protein
sequences, setting a cut-off of the expect value at <10− 10.
All but two sequences belonged to GH18, except for two
sequences of other hypothetical proteins. All sequences were
included in phylogenetic analyses of the proteins, and the
non-GH18 proteins served as outgroup. A total of 101
protein sequences were aligned in Geneious version 6.0.3
(Biomatters Ltd, available from http://www.geneious.com/)
using the ClustalW algorithm (Supplementary Table S3 at
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http://www.biochemj.org/bj/455/bj4550107add.htm). From the
alignment of 1817 amino acids, a region of generally high
coverage comprising 1099 amino acids was extracted and
analysed in BEAST version 1.7.4 [7,26]. We used the Blosum62
substitution model [8,27] with no site heterogeneity specification,
set a strict molecular clock, selected the Yule process [9,28]
for tree prior and ran Bayesian MCMC sampling every
1000 generations for 10 million generations. The output was
examined with Tracer version 1.5 (A. Rambaut and A.J.
Drummond, available from http://beast.bio.ed.ac.uk/Tracer) in
order to ensure that likelihood scores were stationary and that
effective sample sizes were adequate (>500), setting burnin
to 25%. A maximum clade credibility tree was calculated
with TreeAnnotator version 1.7.4 [1,26]. 16S rRNA (RNA or
cDNA) sequences were retrieved from the Ribosomal Project
Database (http://rdp.cme.msu.edu) and GenBank® for taxonomic
analyses of the corresponding taxa/strains in the EndoS dataset
(Supplementary Table S3). In case a specific strain was lacking
for taxa more distantly related in the EndoS protein tree dataset,
another strain was chosen if available. This resulted in a total
of 51 representative sequences, which were aligned according to
the procedures described for the EndoS protein dataset above.
From the resulting alignment of 2172 nt, a high coverage region
comprising 1576 positions was extracted and analysed in BEAST
version 1.7.4 [2–4,26] with similar parameter settings except
for the substitution model [HKY with rate variation across
sites following a discrete gamma distribution (G) with four
rate categories]. Verification and tree calculation followed the
procedures above, and the tree was rooted using the fungal
sequences, which were a part of the dataset, as outgroup.
EndoS2 expression analysis
Overnight cultures of NZ131 in CM were diluted 1:50 and grown
for 16 h at 37 ◦C with 5% CO2 and the cysteine protease inhibitor
E-64 at 20 μM. Glucose, galactose, sucrose, acetylglucosamine
and mannose were added at 0.01% concentration when
indicated. Supernatants were concentrated using precipitation
with 0.3 mM TCA (trichloroacetic acid). The samples and
0.5 μg of recombinant EndoS2 were resuspended in SDS/PAGE
loading buffer and loaded on to a 10 % Bis-Tris gel. The
electrophoresis was performed at 180 V for approximately
60 min and stained with PageBlue Protein Staining Solution
(Fermentas). Blotting on to a PVDF membrane was performed
according to the manufacturer’s instructions using Trans-Blot
Turbo (Bio-Rad Laboratories) equipment. The membrane was
blocked in 5% (w/v) dried skimmed milk powder (Difco)
and incubated with 10 μl of rabbit polyclonal anti-EndoS2 for
1 h at 37 ◦C with rotation. Washing was consistently carried
out in PBST (PBS with 0.05% Tween 20) three times for
10 min. The membrane was washed and incubated with 2.5 μl of
HRP (horseradish peroxidase)-conjugated goat anti-(rabbit IgG)
(H + L) (Bio-Rad Laboratories), washed and developed using
Supersignal West Pico Chemiluminescent Substrate (Thermo
Fisher Scientific). Antiserum against EndoS2 was obtained using
1 mg of recombinant EndoS2 to immunize rabbits following
standard protocols by Davids Biotechnologie, Regensburg,
Germany.
N-glycan hydrolysis assay
A sample of 1 μg of recombinant EndoS2, EndoS2(E186L) or
EndoS or 500 units of PNGase F (peptide N-glycosidase F) was
incubated with 3 μg of IgG or 5 μg of AGP (α1-acid glycoprotein)
(Sigma–Aldrich) in PBS at 37 ◦C for 2 h. For PNGase F,
the substrate was denatured according to the manufacturer’s
instructions (New England BioLabs). Human IgG subclasses
IgG1–4 (Calbiochem/Merck) were incubated with recombinant
EndoS2, EndoS2(E186L) or PBS under the reaction conditions
described above. All reactions were separated on a 10% Bis-
Tris gel as described above. Lectin blotting was performed on
a PVDF membrane (Millipore). The membrane was incubated
in lectin blot buffer (10 mM Hepes, 0.15 M NaCl, 0.1% Tween
20, 0.01 mM MnCl2 and 0.1 mM CaCl2) for 1 h and incubated
with 5 μg of biotinylated LCA (Lens culinaris agglutinin) (Vector
Laboratories) in the same buffer. The membrane was washed three
times for 10 min in lectin blot buffer and subsequently 2.5 μg of
HRP coupled to streptavidin (Vector Laboratories) was added for
1 h. The membrane was developed as described above. The 16 h
bacterial supernatants were concentrated using 10 kDa MWCO
(molecular-mass cut-off) spin columns (Pall) and a functional
assay on the activity of the supernatants on 3 μg of human
serum IgG was performed. The reaction mixture was incubated
at 37 ◦C overnight and analysed by SDS/PAGE (10 % gel) and a
subsequent LCA lectin blot as described above.
Chitinase assay
4MU-GlcNAc (4-methylumbelliferyl N-acetyl-β-D-glucosami-
nide) (Sigma–Aldrich) was incubated at 0.2 mM with 0.3 m-
unit of chitinase from Streptomyces griseus (Sigma–Aldrich)
or 2 μg of rEndoS2 (where r denotes recombinant) or 2 μg of
rEndoS or PBS in 100 μl of PBS. The reactions were incubated
at 37 ◦C for 1 h. Then, 100 μl of 0.1 M glycine (pH 10) was
added to stop the reaction. Absorbance at 355/445 nm was
measured in a black 96-well plate using a spectrophotometer. The
experiments were carried out using five replicates and results are
shown as means+−S.D. The response in absorbance was analysed
statistically by an unpaired Student’s t test, where differences
were considered significant if P<0.05. ****P < 0.001.
Glycoprotein denaturing
A 4 μg amount of IgG or AGP was incubated in 10 μl of PBS
at 37 ◦C, 40 ◦C, 50 ◦C, 60 ◦C, 70 ◦C or 80 ◦C for 30 min. After
the incubation, the samples were kept at 37 ◦C. Then, 2 μg of
rEndoS2 was added to each reaction mixture and incubated further
at 37 ◦C for 2 h. The samples were analysed on a SDS/PAGE
gel and for IgG with LCA lectin blotting as described above.
For analysis of EndoS2 specificity, 4 μg of α2-macroglobulin,
ovalbumin, human lactoferrin, RNase B and fetuin (all Sigma–
Aldrich) were incubated with 2 μg of EndoS2 at 37 ◦C overnight
and subsequently analysed on SDS/PAGE gel as described.
LC–FLD (fluorescence detection)–MS
Online coupled LC–MS with FLD was performed using a Waters
Xevo G2 QTof with Acquity UPLC and BEH (bridged ethane–
silicon hybrid) glycan column (1.0 mm×150 mm, 1.7 μm particle
size). MS data was acquired in negative mode with the following
conditions: 2500 V capillary voltage, 50 V cone voltage, 280 ◦C
desolvation temperature, 600 l·h− 1 desolvation gas and 100 ◦C
source temperature. The analyser was set to sensitivity mode.
The fluorescence data rate was 1 point·s− 1 and a PMT gain of
10 with excitation and emission wavelengths set at 320 nm and
420 nm respectively. Samples were in 80 % acetonitrile with an
injection volume of 10 μl. The flow rate was 0.150 μl·min− 1.
Solvent A was 50 mM ammonium formate (pH 4.4) and solvent
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Figure 1 Genetic context analysis of ndoS and ndoS2
The genetic context of ndoS2 (from NZ131/M49) and ndoS (from MGAS5005/M1) was analysed by aligning and comparing the identity of the sequences in MacVector.
B was acetonitrile. A 40 min linear gradient was used and was as
follows: 28–43% solvent A for 31 min, 70% solvent A for 4 min
and 28% solvent A for 4 min.
Exoglycosidase digestion arrays
Analysis of glycan sequence, composition and linkage
specificities was facilitated by the use of exoglycosidase digestion
arrays. All digestion reactions were performed with enzymes
from Prozyme. Fluorescently labelled glycans were digested
in 50 mM sodium acetate (pH 5.5) at 37 ◦C overnight using a
panel of enzymes with each digestion reaction brought to a final
volume of 10 μl using double-distilled water. Digested glycans
were then separated from the enzyme mixtures using 10 kDa
MWCO centrifugal filters. Digested 2-AB (2-aminobenzamide)-
labelled glycans were then prepared for separation on UHPLC
(ultra-HPLC) with fluorescence detection using a BEH glycan
column as described previously [5,29]. Specific non-reducing
end monosaccharides were removed as follows: terminal
sialic acid in all linkages was removed with 1 m-unit·μl− 1
ABS (Arthrobacter ureafaciens sialidase); terminal galactose
monosaccharides were removed using 0.5 m-unit·μl− 1 BTG
(bovine testes β-galactosidase), which releases both β(1,3)- and
β(1,4)-linked galactose; terminal GlcNAc monosaccharides were
released with 40 m-unit·μl− 1 GUH (Streptococcus pneumoniae
hexosaminidase), capable of cleaving β-linked GlcNAc moieties;
core α(1,6)-fucose was selectively removed using 1 m-unit·μl− 1
BKF (bovine kidney α-fucosidase), (2,3)-linked sialic acid
was removed using 10 m-unit·μl− 1 recombinant Streptococcus
pneumoniae NAN1 (neuraminidase/sialidase 1), and AMF
(almond meal α-fucosidase) at 6 m-unit·μl− 1 was used to release
(1,3)- and (1,4)-linked non-reducing terminal fucose residues.
Activity of EndoS2 on free N-glycans
N-glycans present on 80 μg of bovine fetuin (Sigma–Aldrich)
were released using 2500 units of PNGase F (New England
BioLabs), and labelled with 2-AB (Ludger). The labelled fetuin
2-AB glycan pool was then incubated at 37 ◦C for 16 h in
the presence of 80 μg·ml− 1 EndoS2 in PBS to determine the
activity of EndoS2 on free N-glycans. The resulting EndoS2-
digested glycan pool was then relabelled with 2-AB. Each
glycan preparation was separated using a 1.7 μm BEH glycan
column (2.1 mm×150 mm, Waters) and analysed by UHPLC–
FLD–MS using a Waters ACQUITY UPLC® H-Class Bio with
fluorescence detection coupled to a Waters Xevo G2-S Q-ToF
mass spectrometer. The column temperature was 40 ◦C with a flow
rate of 0.4 ml·min− 1 using a linear gradient of 50 mM ammonium
formate (pH 4.4) against acetonitrile with ammonium formate
increasing from 30% to 47% over a 32 min period. Fluorescence
detection was achieved using excitation and emission wavelengths
of 330 nm and 420 nm respectively. Eluting glycans were detected
in positive mode with the following settings: cone voltage of
80 V, capillary voltage of 3.0 kV, source temperature of 120 ◦C,
desolvation temperature of 300 ◦C, and desolvation gas flow of
800 l·h− 1. Mass data were acquired using sensitivity mode with
a mass range of 750 m/z to 2000 m/z with a 1.0 s scan time. Both
LC–FLD and LC–MS data were acquired and processed using
Waters UNIFI version 1.6.
RESULTS
Identification of EndoS2 from GAS serotype M49
In the sequenced genome of GAS strain NZ131 (serotype M49),
we identified ndoS2, a gene harbouring a GH18 domain [6,24].
ndoS2 from GAS serotype M49 was found in the same genetic
context as ndoS from GAS serotype M1, but showed only 53 %
nucleotide identity with ndoS (Figure 1). The surrounding genes,
i.e. scrb, scra, scrk and pmi, showed a high degree of nucleotide
identity when comparing the chromosomal context between strain
NZ131 and serotype M1 strain MGAS5005 (Figure 1). One
genome of serotype M49 is available to the public (NZ131,
GenBank® accession number NC_011375) and therefore ndoS2
was sequenced in five M49 strains of different origin and isolation
year (3487-05, ACN49, AP49, AW1 and AW2). The comparison
revealed 100% identity of ndoS2 in the five selected strains
compared with ndoS2 found in NZ131. The ndoS2 sequences
have been submitted to GenBank® (Supplementary Table S1).
The deduced amino acid sequence of EndoS2 and EndoS revealed
37% identity when aligned using ClustalW (Figure 2). The signal
peptide was conserved, but three major sections of the EndoS
amino acid sequence were lacking in EndoS2; at positions 45–
83, 535–561 and 933–986, gaps can be seen in the alignment.
A comparison of the active site of EndoS2 and EndoS revealed
the GH18 motif (DXXDXDXE) with glutamate at position 186
as the catalytic amino acid to be conserved (Figure 2). Specific
tryptophan residues have previously been shown to be important
for the enzymatic activity of EndoS, and when EndoS2 was aligned
and compared with EndoS, tryptophan residues at positions 121,
164, 332, 361, 391, 809, 828 and 907 were found to be conserved
[10–13].
In order to evaluate the evolutionary history of EndoS2,
we reconstructed a protein specific phylogenetic tree, using
BEAST version 1.7.4, on 101 protein sequences selected with
the BLASTP algorithm on EndoS2. EndoS2 (depicted in blue)
was found to be unique to GAS serotype M49 and relatively
different from EndoS found in other serotypes of GAS as
well as EndoS-like proteins in other Streptococcus species
(Figure 3). This can be contrasted with the taxonomic phylogeny
of the 16S rRNA sequences (Supplementary Figure S1 at
http://www.biochemj.org/bj/455/bj4550107add.htm).
EndoS2 hydrolyses the N-linked glycan on the heavy chain of IgG
Previous work has concluded that EndoS hydrolyses the N-linked
glycan on IgG [10,13]. Although the enzymes are different, we
tested whether IgG is a substrate for EndoS2. A comparison of
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Figure 2 ClustalW alignment of EndoS2 and EndoS
EndoS2 from GAS strain NZ131 and EndoS from GAS strain MGAS5005 was aligned using ClustalW. Depicted in blue is the GH18 active site (DXXDXDXE) and in green are conserved tryptophan
residues.
the hydrolysis of the N-linked glycan on the heavy chain of IgG
was carried out using EndoS2, EndoS and PNGase F as positive
control [14,30]. PNGase F from Elizabethkingia meningoseptica
cleaves between the GlcNAc and the asparagine residue of N-
linked glycans, whereas EndoS cleaves between the two GlcNAc
moieties in the chitobiose core of N-linked glycans [10,11].
EndoS2 was mutated in the active site through site-directed
mutagenesis where the catalytically active glutamate residue was
mutated to leucine, creating the enzyme EndoS2(E186L). EndoS2,
EndoS2(E186L), EndoS and PNGase F were incubated with
human IgG in PBS at 37 ◦C overnight, and analysed by SDS/PAGE
and a subsequent LCA (recognizing α-linked mannose) lectin blot
(Figure 4A). The gel shows a ∼4 kDa shift of the heavy chain of
IgG and a corresponding lack of LCA lectin signal when incubated
with EndoS2, EndoS or PNGase F, but not with EndoS2(E186L)
or PBS (Figure 4A). This result indicates that EndoS2 hydrolyses
the N-linked glycan on the heavy chain of IgG and confirms the
glutamate residue at position 186 of EndoS2 to be the catalytically
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Figure 3 Phylogenetic reconstruction of the protein-specific tree for EndoS-like proteins, based on 1099 amino acids
All internal nodes were supported by a Bayesian posterior probability (PP) of 0.99–1.0 except for nodes highlighted with grey squares (0.80<PP<0.95) or black squares (PP<0.80). The scale bar
indicates genetic distance. Non-verified hypothetical proteins predicted from gene models are indicated with grey branches, the EndoS2 clade is highlighted in blue and the fungal clade is highlighted
in red. For accession numbers, see Supplementary Table S3 at http://www.biochemj.org/bj/455/bj4550107add.htm.
active amino acid. To evaluate enzymatic activity of EndoS2 on the
subclasses of IgG, recombinant EndoS2 and EndoS2(E186L) were
incubated with human IgG subclasses 1–4 and showed activity
on all four human subclasses as analysed by SDS/PAGE and
LCA lectin blot (Figure 4B). The glycan-hydrolysing activity
of EndoS2 on animal IgG was found for the following species:
mouse, rat, monkey, sheep, goat, cow and horse. To investigate
glycan specificity of EndoS2, the composition of the released
glycans from pooled human serum IgG was analysed by HILIC
(hydrophilic interaction liquid chromatography)–UHPLC–FLD–
MS and compared with the glycan profile of IgG generated by
PNGase F (Figure 5). The HILIC–UHPLC–FLD–MS revealed
EndoS2 to cleave between the two GlcNAc residues in the
chitobiose core of the N-linked glycan and thus leaving a single
GlcNAc residue with or without α(1,6)-linked fucose attached
to the protein backbone. All peaks present in the PNGase F
chromatogram could be found in the glycan profile of IgG released
by EndoS2 with the difference of one GlcNAc with or without
α(1,6)-linked fucose.
EndoS2 releases biantennary and sialylated glycans on AGP
AGP, also known as orosomucoid, is a 41–45 kDa human
plasma glycoprotein, a major positive acute-phase protein, up-
regulated severalfold during inflammation and a member of the
lipocalin family [11,31]. The immunomodulatory effects of AGP
is linked to the carbohydrate composition of the five N-linked
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Figure 4 Activity of EndoS2 on IgG, IgG subclasses and AGP
(A) Human serum IgG was incubated with recombinant EndoS2, EndoS2(E186L), EndoS, PNGase
F or PBS at 37◦C in PBS overnight and analysed by SDS/PAGE (10 % gel) and a subsequent LCA
blot. The gel and lectin blot shows the γ heavy chain of IgG at 50 kDa. (B) Human subclasses of
IgG, IgG1–4, were incubated with recombinant EndoS2, EndoS2(E186L) or PBS in PBS at 37◦C
overnight and analysed by SDS/PAGE (10 % gel) and a subsequent LCA lectin blot. (C) AGP
was incubated with recombinant EndoS2, EndoS or PBS at 37◦C in PBS overnight and analysed
by SDS/PAGE (10 % gel).
glycans (Asn33, Asn56, Asn72, Asn93 and Asn103) that make up
45% of the molecular mass [15,31]. When incubating AGP
with recombinant EndoS2, subsequent SDS/PAGE revealed a
new band at ∼38 kDa and a decrease in the intensity of the
band at 45 kDa (Figure 4C). No activity was detected with
EndoS or PBS in the same assay (Figure 4C). To elucidate the
enzymatic activity of EndoS2 on AGP in detail, we analysed
the glycans released from AGP by EndoS2 using HILIC–UHPLC–
FLD–MS and exoglycosidase arrays in UHPLC (Figure 6). The
sequence, composition and linkage specificities of all glycoforms
of AGP released by PNGase F were determined in the same
way to serve as control. EndoS2 was found to cleave only
biantennary and sialylated structures of AGP, whereas the glycan
profile from PNGase F contained sialylated bi-, tri- and tetra-
antennary structures with or without outer arm fucosylation.
The cleavage site of EndoS2 was confirmed to be between
the two GlcNAcs in the chitobiose core of the glycan. The
glycan profiles were digested with NAN1 to remove α(2,3)-
linked sialic acids and ABS to remove α(2,3)-, α(2,6)- and
α(2,8)-linked sialic acid residues. The resulting bi-, tri- and tetra-
antennary structures from AGP were identified as M − 2H2 − ions
(m/z 879.3, 1061.9, 1135.5, 1244.5 and 1317.5). Furthermore,
glycans were digested with linkage-specific exoglycosidases
to verify the presence of outer arm fucosylation. These
Figure 5 Glycan fluorescent profiles from human IgG released by EndoS2
and PNGase F
HILIC–FLD–MS of 2-AB-labelled glycans released from human serum IgG by EndoS2 (A) and
PNGase F (B) respectively. Identified glycan structures are presented using the Oxford glycan
nomenclature [45].
enzymes were BTG, BKF and AMF (Supplementary Figure
S2 at http://www.biochemj.org/bj/455/bj4550107add.htm). AMF
digestion removed α(1,3) non-reducing terminal fucose linked to
galactose residues and not core α(1,6)-fucose. BKF treatment,
which is specific for core α(1,6)-linked fucose residues, did not
result in glycan digest products.
EndoS2 is specific for IgG and AGP and not a general chitinase
Previous work on EndoS has shown that the enzyme is specific
for the native form of IgG [14]. To test whether this is valid for
EndoS2, IgG and AGP were incubated at temperatures ranging
from 37 to 80 ◦C or 37 to 70 ◦C for 30 min before the addition
of EndoS2 or PBS and a 2 h incubation at 37 ◦C. SDS/PAGE
analysis revealed a shift of IgG incubated at 37–50 ◦C and
loss of signal was seen in a corresponding LCA lectin blot,
whereas only partial shift could be seen at 60 ◦C and no shift and
intact LCA signal at temperatures 70 ◦C and 80 ◦C (Figure 7A).
Glycans from AGP were hydrolysed at 37 ◦C, but not at 40–70 ◦C
(Figure 7B). The activity of EndoS2 was tested further on a range
of glycoproteins, i.e. α2-macroglobulin, ovalbumin, lactoferrin,
RNase B and fetuin, but no activity could be detected (Figure 7C).
To study whether EndoS2 shows general chitinase activity, we
employed the substrate 4MU-GlcNAc, which fluoresces when
cleaved, to compare the enzymatic activity of EndoS2 and EndoS
with that of a chitinase from S. griseus. The results indicate
that neither EndoS2 nor EndoS has a general chitinase activity
compared with the positive control (Figure 7D).
EndoS2 hydrolyses free biantennary glycans
Following the findings of the specificity of EndoS2, we asked
the question whether the enzyme is substrate-specific and/or has
glycoform selectivity. To test this, we analysed the activity of
EndoS2 on free glycans. All glycoforms from bovine fetuin were
released using PNGase F and were 2-AB-labelled; in a secondary
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Figure 6 Glycan fluorescent profiles from human AGP released by PNGase F and EndoS2
HILIC–FLD–MS of 2-AB-labelled glycans released from human AGP by PNGase F (left) and EndoS2 (right) respectively. 2-AB-labelled glycans were digested further with NAN1 and ABS, and
subsequent bi-, tri- and tetra-antennary structures are indicated using the Oxford glycan nomenclature [45]. Ions were detected as [M − 2H]2 − (**) and [M − H]− (*) species.
Figure 7 Activity of EndoS2 on native and denatured IgG and AGP, other glycoproteins and chitinase assay
(A) IgG was incubated at temperatures ranging from 37 to 80◦C for 30 min followed by incubation with EndoS2 at 37◦C for 2 h and analysis by SDS/PAGE and LCA lectin blot. (B) AGP was
incubated at 37–70◦C followed by incubation with EndoS2 at 37◦C for 2 h and analysis by SDS/PAGE. (C) EndoS2 was incubated with α2-macroglobulin, ovalbumin, human lactoferrin, RNase B
and fetuin at 37◦C overnight and analysed by SDS/PAGE. (D) EndoS2, EndoS and a chitinase from S. griseus was incubated with the fluorescent substrate 4MU-GlcNAc for 1 h and fluorescence
was measured at 355/445 nm. The experiments were carried out using five replicates and results are means+−S.D. The response in absorbance was analysed statistically by an unpaired Student’s t
test, where differences was considered significant if P<0.05. ****P<0.001.
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Figure 8 EndoS2 hydrolyses biantennary free glycans
Bovine fetuin N-glycans were released with PNGase F, labelled with 2-AB, and analysed by HILIC–UHPLC–FLD–MS. Released N-glycans were digested further with EndoS2 to determine enzymatic
activity on free glycans. Comparison of the fluorescent chromatograms of glycans after PNGase F (B) and subsequent EndoS2 digestion (A) identified three unique peaks (labelled 1, 2 and 3).
These peaks correspond to three isomeric structures (A2G2, A2G2S1 and A2G2S2) and were detected primarily as m/z 1558.55 [M + H]+ , 925.33 [M + 2H]2 + and 1070.87 [M + 2H]2 + ions
respectively (C)–(E). Extracted ion chromatograms of A2G2S1 and A2G2S2 precursor ions identified structural isomers, presumably from variation in sialic acid linkages.
reaction, the free glycans were incubated with EndoS2, relabelled
with 2-AB and analysed using HILIC–UHPLC–FLD–MS. Three
structures in the chromatogram (labelled 1, 2 and 3) were modified
by EndoS2 compared with the PNGase F glycan pool (Figure 8A
and 8B). The m/z of the [M + H]+ ions of these structures were
identified and revealed structures for A2G2 (1558.5513), A2G2S1
(925.3294) and A2G2S2 (1070.8700) less one GlcNAc residue
(Figures 8C–8E). The results indicate that EndoS2 specifically
hydrolyses free biantennary glycoforms with or without terminal
sialylation.
Expression of EndoS2 is linked to carbohydrate utilization
To confirm the findings with recombinant EndoS2, the expression
levels and enzymatic activity of EndoS2 were analysed in GAS
supernatants. The expression of EndoS in serotype M1 of GAS
is maximized in the nutrient-poor CM [10,16–21]. Therefore
expression of EndoS2 was analysed by Western blotting of 16 h
bacterial supernatants grown in CM. However, EndoS2 could only
be detected in the supernatant when GAS was cultured in 50%
diluted CM, when the bacteria are starved (Figure 9A). In a
subsequent functional assay incubating IgG with the bacterial
supernatant, loss of the N-linked glycan on IgG was visualized
as a 4 kDa shift of the heavy chain on the electrophoresis gel and
corresponding lack of signal in the LCA lectin blot (Figure 9B).
This experiment confirmed the activity of the native protein in the
bacterial supernatant. The expression of EndoS2 in poor medium
led us to believe that the expression of EndoS2 was linked to the
carbohydrate utilization of the bacteria [22,23,32]. To address
this, a selection of carbohydrates was added to the bacterial
culture medium and the expression of EndoS2 was studied. Adding
glucose, galactose, GlcNAc or mannose to 50% CM inhibited
EndoS2 expression, whereas additional sucrose increased the
amount of EndoS2 in the supernatant (Figure 9A).
DISCUSSION
The study of bacterial glycosidases has emerged as a field at
the intersection of microbial pathogenesis and glycobiology. By
studying the mechanisms by which bacteria interfere with host
glycosylation, new insight can be gained into both bacterial
pathogenesis and the impact of glycosylation of the immune
system. Interfering with the glycosylation of the host defence
is widespread among pathogenic bacteria for modulation of the
functions of the immune system or as a way of utilizing the glycans
of glycoproteins as nutrients [24,33].
For example, Enterococcus faecalis, a Gram-positive gut
bacterium and opportunist, secretes EndoE, an endoglycosidase
with activity on the Fc-glycan on IgG and on the glycoprotein
RNase B that promotes bacterial growth when nutrients are scarce
[24,34]. The endoglycosidases EndoF1–3 from E. meningoseptica
and EndoH from Streptomyces plicatus has been shown to be
glycan-specific: high-mannose and hybrid oligosaccharides are
cleaved by EndoF1 and EndoH, whereas complex biantennary
and bi- and tri-antennary glycans are released by EndoF2 and
EndoF3 respectively [24,25,35–38]. An N-glycan deglycosylation
complex in Capnocytophaga canimorsus has been found to cleave
off N-linked glycans from IgG and to transport the glycans
across the cell membrane for glycan catabolism [24,25,39]. S.
pneumoniae has three surface-anchored exoglycosidases that
work in concert to remove sialic acid, galactose and GlcNAc
on human glycoproteins [40]. GAS EndoS was thought to
be conserved throughout the GAS serotypes, and only minor
variations are found when comparing ndoS among the sequenced
GAS strains. It was therefore surprising to find that GAS strain
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Figure 9 EndoS2 expression and activity in GAS strain NZ131
(A) Western immunoblot showing EndoS2 in bacterial supernatants with or without added
carbohydrates. rEndoS2 was used as a positive control. (B) Lectin blot analysis of human IgG
incubated with bacterial supernatants with or without carbohydrates, or rEndoS2 as a positive
control.
NZ131 harboured ndoS2, with 53% identity with ndoS. The
sequenced ndoS2 in five different M49 strains revealed high
identity, arguing that this gene is conserved throughout the
serotype.
In the phylogenetic protein tree, the EndoS2 group is relatively
different from EndoS in both S. pyogenes and in other
Streptococcus species (but it groups with a hypothetical protein
found in Streptococcus ictaluri). In general, the patterns are not
uniform: whereas within-species or within-genus similarity of
the EndoS-like proteins is high for some taxonomic groups (e.g.
Bifidobacterium longum), there is also considerable within-genus
variation in Corynebacterium (Figure 3). Strikingly, EndoS and
EndoS2 from Streptococcus are more closely related to EndoS-like
proteins of the fungi Cordyceps militaris and Beauveria bassiana
than to EndoS-like proteins of bacteria such as Melissococcus,
Corynebacterium and Lactobacillus (Figure 3), in sharp contrast
with the taxonomic relationships (Supplementary Figure S1).
Notably, some taxa are paraphyletic in the EndoS-like protein
phylogeny, to which could possibly be ascribed the inclusion
of non-verified hypothetical proteins. However, the biologically
verified EndoS-like proteins of Enterococcus gallinarum and E.
faecalis do not form a monophyletic clade (Figure 3). In all, this
picture indicates the occurrence of horizontal gene transfer of
ndoS-like genes. Even though no known proteins were found to
be closely related to EndoS2, the differentiation from S. pyogenes
EndoS and the high degree of similarity between serotype M49
and other S. pyogenes strains combined with the conserved genetic
context points towards horizontal gene transfer of ndoS2 into
serotype M49. The strain NZ131 also has an unusually high
frequency of transformation, and horizontal gene transfer has been
described on several places in the genome [24]. The alternative
interpretation, that a particularly strong directional selection on
the ancestral ndoS gene in serotype M49 resulted in ndoS2, seems
less plausible.
The active site and tryptophan residues important for activity
in EndoS were found to be conserved in EndoS2 even though
the proteins are only 37 % identical [13]. Despite this substantial
difference in amino acid sequences, EndoS2 hydrolysed the glycan
on IgG in a similar fashion to EndoS. In the chromatograms
comparing the glycan profile of IgG generated by EndoS2 and
PNGase F (Figure 5), a shift was observed that could be explained
by the site of action. PNGase F is an amidase that cleaves between
the asparagine residue and the first GlcNAc residue of the glycan,
whereas EndoS2 cleaves after the first GlcNAc and thus leaves one
GlcNAc with or without fucose attached to the protein backbone.
Owing to lack of one reducing end GlcNAc in the EndoS2 glycan
profile, there is a loss in resolution, which explains why the A2G1
peak could not be separated in the EndoS2 chromatogram, but can
be seen as two separate peaks in the PNGase F profile. It has been
argued previously that EndoS does not cleave bisecting glycans
[41,42]. From the LC–MS data of the present study, we argue
that EndoS2 cleaves all glycoforms present of human serum IgG,
including bisecting glycans, since all peaks present in the PNGase
F glycan profile could be found in the EndoS2 profile (Figure 5).
A striking difference between EndoS2 and EndoS was found
when incubated with the human acute-phase protein AGP.
The observed activity of EndoS2 was confirmed with LC–
MS and revealed that EndoS2 specifically releases biantennary
and sialylated structures of AGP (Figure 6). Again, the peaks
annotated in the EndoS2 profile could be found in the PNGase F
release with the difference of one GlcNAc residue. It is clear that
EndoS2 only releases a fraction of the glycans present on AGP.
EndoS2 does not cleave tri- and tetra-antennary glycans, with or
without outer arm fucosylation, although they are present in great
numbers on AGP.
The activity on IgG and AGP raised several questions regarding
the specificity of EndoS2. To answer these, we tested the activity of
EndoS2 on heat-denatured IgG and AGP, on other glycoproteins,
in a chitinase assay and on a pool of free N-glycans. EndoS2
was only active on native IgG and AGP and we draw the
conclusion that EndoS2 requires a protein–protein interaction
with its substrates for glycan hydrolysis to occur. The activity of
EndoS2 on AGP may be the result of reduced protein recognition,
since early studies indicate sequence homology between IgG
and AGP [43]. On glycoproteins with a completely different
fold, we detected no activity with similar assays to the activity
on IgG and AGP detected. It was therefore not surprising to
find that EndoS2 had no general chitinase activity compared
with a chitinase from S. griseus. Taken together, these data
indicate that EndoS2 specifically interacts with protein folds
including IgG and AGP. Furthermore, we dissected the glycoform
specificity of EndoS2 by incubating the enzyme with the N-
glycan pool from fetuin released by PNGase F and showed
that EndoS2 hydrolysed only free biantennary structures with or
without terminal sialylation. No bisecting glycans are present on
fetuin, which explains why such structures are not present in the
chromatograms. On the basis of our findings, we believe that
EndoS2 is both site- and glycoform-specific which is a unique
property of an endoglycosidase.
The hydrolysis of the glycan of IgG has been shown to have
major consequences on the effector functions of the antibody by
modulating the binding to Fcγ R [12]. Since EndoS and EndoS2
have similar hydrolysing activity on the glycan of IgG, both
enzymes are expected to affect the functionality of this antibody.
The functional consequence for AGP when biantennary sialylated
glycans are cleaved off is unknown and lies beyond the scope of
the present study.
The expression of EndoS2 was found to depend on the
availability of carbohydrates in the bacterial culture medium. C-
medium is a poor medium for GAS and expression of EndoS2
could only be detected when GAS was grown in 50% diluted
C-medium. Incubating the supernatants with IgG confirmed the
previous work carried out with recombinant EndoS2 and a clear
correlation between expression of EndoS2 and hydrolysis of the
Fc-glycan on IgG confirmed this. The genes scrb, scra and scrk,
surrounding ndoS2, are part of a sucrose utilization operon and this
could explain the increase of EndoS2 expression when sucrose was
added to the culture medium. The presence of glucose, galactose,
GlcNAc or mannose completely inhibited expression of EndoS2
indicating that this enzyme is tightly regulated by a mechanism
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sensitive to the presence of carbohydrates. Research has indicated
that the virulence of GAS is linked to the utilization of available
carbohydrates via CcpA (catabolite control protein A), but in the
present study of EndoS2, we can only hypothesize that CcpA is
involved in the regulation mechanism [32]. This indicates that in
the infection scenario, EndoS2 is strictly regulated and that the
enzyme is used in an environment where nutrition is scarce, e.g.
the human skin. This indicates further that the virulence of GAS
is linked to the utilization of complex carbohydrates [44].
The present study shows that the endoglycosidase EndoS2 is
conserved and uniquely present in GAS serotype M49. We show
that EndoS2 hydrolysed all glycoforms on human serum IgG and
biantennary and sialylated glycans on AGP. EndoS2 is secreted
by GAS during starvation and the expression is linked to the
carbohydrate composition of the culture medium. The enzymatic
activity on two key players of the immune system argues that
EndoS2 has a role in immunomodulation of the host that could
potentially be linked to the pathogenesis of GAS serotype M49
infections.
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experiments and drafted the paper. Weston Struwe, Eoin Cosgrave and Pauline Rudd
performed glycan analysis and contributed to the paper. Martin Stervander performed
phylogenetic analyses and contributed to the paper. Victor Nizet, Andrew Hollands and
Maria Allhorn provided material and valuable input on the text. All authors read
and approved the final paper.
FUNDING
This work was supported by the Swedish Research Council [grant number 2010-57X-
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EndoS2 is a unique and conserved enzyme of serotype M49 group A
Streptococcus that hydrolyses N-linked glycans on IgG and α1-acid
glycoprotein
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Figure S1 Phylogenetic reconstruction of 16S rRNA sequences, for
inference of taxonomic relationship between taxa of the EndoS-like protein
phylogeny, based on 1576 nucleotides
All internal nodes were supported by a Bayesian posterior probability (PP) of 0.99–1.0 except
for the grouping of the Listeriaceae family bacterium, highlighted with a black squares signifying
PP<0.80. The scale bar indicates genetic distance. Note that the branches connecting the
ingroup and outgroup are truncated owing to the large taxonomic difference (genetic distances
stated below branches). For accession numbers, see Table S3.
1 To whom correspondence should be addressed (email jonathan.sjogren@med.lu.se).
2 Patents for the use of EndoS2 have been applied for by Genovis AB. Jonathan Sjögren, Andrew Hollands, Victor Nizet, Maria Allhorn and Mattias
Collin are listed as inventors on the application that is pending.
3 Present address: Chemistry Research Laboratory, Department of Chemistry, University of Oxford, Oxford OX1 3TA, U.K.
4 Present address: Waters Corporation, 34 Maple Street, Milford, MA 01757, U.S.A.
The sequences of Streptococcus pyogenes ndoS2 will appear in the DDBJ, EMBL, GenBank® and GSDB Nucleotide Sequence Databases under
accession numbers KC155346 (strain 3487-05), KC155348 (strain AP49), KC155347 (strain ACN49), KC155349 (strain AW1) and KC155350 (strain AW2).
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Figure S2 HILIC–FLD–MS and exoglycosidase sequencing of AGP N-glycans
The fucose linkage position was confirmed as α(1,3) to galactose residues on tri- and tetra-antennary glycans and were detected as [M − 2H]2 − ions 972.9 and 1074.5.
Table S1 E. coli and group A streptococcal strains used in the present study
Strains of E. coli and S. pyogenes with accession numbers. Also indicated is the GenBank® accession number for ndoS2 sequences. N/A, not applicable.
Strain Source/accession number ndoS2 accession number
E. coli
Top10 Invitrogen N/A
BL21 pLysS Invitrogen N/A
GAS (serotype)
NZ131 (M49) ASM1812v1 ACI61688
3487-05 (M49) S. pyogenes, serotype M49 KC155346
ACN49 (M49) Strain 3274-98 from Center for Disease Control and prevention. A gift from Actinova KC155347
AP49 (M49) S. pyogenes strain collection, Institute of Hygiene and Epidemiology, Prague, Czech Republic KC155348
AW1 (M49) Nephritis strain H 9449 B from the collection of L. Wannamaker KC155349
AW2 (M49) Strain H 5424 from the collection of L. Wannamaker KC155350
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Table S2 Plasmids and primers used in the present study
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Table S3 Accession numbers for EndoS-like protein and 16S rRNA sequences
For the EndoS-like protein dataset, outgroup sequences are indicated with an asterisk. For the EndoS2 sequences of the present study, see Table S1.
GenBank® accession number
Taxa Strain EndoS-like protein 16S rRNA
Actinomyces neuii BVS029A5 ZP_11040533
Beauveria bassiana ARSEF 2860 EJP67240
Bifidobacterium longum subsp. infantis 157F YP_004209228 AP010890
Bifidobacterium longum subsp. infantis ATCC 15697 YP_002323900 AP010889
Bifidobacterium longum subsp. longum 44B EIJ32132
Bifidobacterium longum subsp. longum 1-6B EIJ25186
Brachybacterium faecium DSM 4810 YP_003153977; YP_003155571 X91032
Carnobacterium maltaromaticum ATCC 35586 ZP_10279268 JF749289
Carnobacterium maltaromaticum LMA28 YP_006993899
Chryseobacterium meningosepticum ATCC 13254 AJ704541
Cordyceps militaris CM01 EGX89767 HQ585075
Corynebacterium diphtheriae 241 YP_005126330 CP003207
Corynebacterium diphtheriae BH8 YP_005161243 CP003209
Corynebacterium diphtheriae C7 (β) YP_005163607 CP003210
Corynebacterium diphtheriae CDCE 8392 YP_005134619 CP003211
Corynebacterium diphtheriae INCA 402 YP_005128539 CP003208
Corynebacterium diphtheriae PW8 YP_005143699 CP003216
Corynebacterium diphtheriae 31A YP_005158899
Corynebacterium diphtheriae bv. intermedius str. NCTC 5011 EIK55328
Corynebacterium pseudotuberculosis 31 YP_006214375 CP003421
Corynebacterium pseudotuberculosis 258 YP_006353466 CP003540
Corynebacterium pseudotuberculosis Cp162 YP_006437976 CP003652
Corynebacterium pseudotuberculosis FRC41 YP_003784295 CP002097
Corynebacterium pseudotuberculosis PAT10 YP_005691331 CP002924
Corynebacterium pseudotuberculosis X81907
Corynebacterium pseudotuberculosis 316 YP_005304514 CP003077
Corynebacterium pseudotuberculosis CIP 52.97 YP_005695446
Corynebacterium ulcerans 809 YP_005711595 CP002790
Corynebacterium ulcerans BR-AD22 YP_004630749 CP002791
Elizabethkingia anophelis Ag1 ZP_09415888 EF426425
Elizabethkingia meningoseptica EBA2 FLAME
Enterococcus faecalis ATCC 29200 ZP_04439322 ACHK01000081
Enterococcus faecalis OG1RF CP002621
Enterococcus faecalis V583 NP_813917
Enterococcus faecalis HER1044 AAR20477
Enterococcus faecalis DS5 ZP_05561082
Enterococcus faecalis ERV85 EJV36587
Enterococcus faecalis PC1.1 ZP_06746878
Enterococcus faecalis R508 EJV39420
Enterococcus faecalis R712 ZP_06630726
Enterococcus faecalis T1 ZP_05422239
Enterococcus faecalis T2 ZP_05425204
Enterococcus faecalis T3 ZP_05502539
Enterococcus faecalis T8 ZP_05560447
Enterococcus faecalis TX0012 EFT95260; EFT95516; EFT95520
Enterococcus faecalis TX0104 ZP_03950001
Enterococcus faecalis TX0109 ZP_07567140
Enterococcus faecalis TX0309B EFU85828
Enterococcus faecalis TX0470 ZP_07760464
Enterococcus faecalis TX0855 ZP_07555326
Enterococcus faecalis TX0860 ZP_07559314
Enterococcus faecalis TX1322 ZP_04435748
Enterococcus faecalis TX1341 EFU12187
Enterococcus faecalis TX1342 EFU15396
Enterococcus faecalis TX1346 EFU16620
Enterococcus faecalis TX1467 EGG58918
Enterococcus faecalis TX2137 EFT38634
Enterococcus faecalis TX4244 EFT91060
Enterococcus gallinarum EG2 ZP_05648160
Enterococcus saccharolyticus 30_1 ZP_09110633
Helcococcus kunzii ATCC 51366 ZP_09737336; ZP_09738693
Helcococcus kunzii 22 NR_029237
Helcococcus kunzii M112 JN861738
Lactobacillus zeae KCTC 3804 ZP_09453558
Lactococcus garvieae ATCC 49156 YP_004779109 AP009332
Listeriaceae family bacterium TTU M1-001 ZP_09890591 JQ287762
Melissococcus plutonius ATCC 35311 YP_004455741 AP012200
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Table S3 Continued
GenBank® accession number
Taxa Strain EndoS-like protein 16S rRNA
Melissococcus plutonius DAT561 YP_005320150 AP012282
Paenibacillus alvei DSM 29 ZP_10866627 AJ320491
Paenibacillus dendritiformis C454 ZP_09678120
Paenibacillus popilliae ATCC 14706 GAC41484 AB073198
Streptococcus canis FSL Z3-227 ZP_10274531
Streptococcus equi subsp. equi 4047 YP_002745815 FM204883
Streptococcus equi subsp. zooepidemicus MGCS10565 YP_002122753 CP001129
Streptococcus equi subsp. zooepidemicus ATCC 35246 AEJ24585 CP002904
Streptococcus equi subsp. zooepidemicus H70 YP_002745127
Streptococcus ictaluri 707-05 ZP_09127116; ZP_09126970∗
Streptococcus ictaluri 706-05 DQ462420
Streptococcus iniae 9117 ZP_11067943
Streptococcus pyogenes Alab49 YP_006072662 CP003068
Streptococcus pyogenes M1 GAS NP_269818 AE006615
Streptococcus pyogenes MGAS315 NP_665372 AE014074
Streptococcus pyogenes MGAS5005 YP_282903 CP000017
Streptococcus pyogenes MGAS6180 YP_280992 CP000056
Streptococcus pyogenes MGAS8232 NP_607886 AE009954
Streptococcus pyogenes MGAS9429 YP_597275 CP000259
Streptococcus pyogenes MGAS10270 YP_599216 CP000260
Streptococcus pyogenes MGAS10394 YP_060848 CP000003
Streptococcus pyogenes MGAS10750 YP_603093 CP000262
Streptococcus pyogenes MGAS15252 YP_005389405 CP003116
Streptococcus pyogenes str. Manfredo YP_001127900 AM295007
Streptococcus pyogenes NZ131 YP_002286383 CP000829
Streptococcus pyogenes ATCC 10782 ZP_07460044
Streptococcus pyogenes HKU QMH11M0907901 EIK41346
Streptococcus pyogenes M49 591 ZP_00365754
Streptococcus pyogenes CS101 U78969_1∗
Streptococcus sp. group C C116 ADC53484
Trichosporon asahii var. asahii CBS 2479 EJT46459
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